Humanized anti-CD117 Monoclonal Antibody (JSP191)
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MYELODYSPLASTIC SYNDROME; MDS
Conditions
MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
Trial Timeline
Jul 8, 2020 → Dec 8, 2023
NCT ID
NCT04429191About Humanized anti-CD117 Monoclonal Antibody (JSP191)
Humanized anti-CD117 Monoclonal Antibody (JSP191) is a phase 1 stage product being developed by Jasper Therapeutics for MYELODYSPLASTIC SYNDROME; MDS. The current trial status is unknown. This product is registered under clinical trial identifier NCT04429191. Target conditions include MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04429191 | Phase 1 | UNKNOWN |
| NCT02963064 | Phase 1/2 | Terminated |
Competing Products
20 competing products in MYELODYSPLASTIC SYNDROME; MDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 28 |
| JSP191 | Jasper Therapeutics | Phase 1 | 25 |
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 33 |
| Erlotinib Hydrochloride | Astellas Pharma | Phase 2 | 52 |
| Decitabine + Decitabine + Decitabine | Eisai | Phase 2 | 52 |
| Decitabine + Valproic Acid | Eisai | Phase 2 | 52 |
| decitabine + decitabine | Eisai | Phase 2 | 52 |
| decitabine + azacitidine | Eisai | Approved | 85 |
| Decitabine | Eisai | Phase 2 | 52 |
| decitabine + decitabine + decitabine + decitabine | Eisai | Phase 1 | 33 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid | Eisai | Phase 2 | 52 |
| Subcutaneous Decitabine | Eisai | Phase 1 | 33 |
| Decitabine | Eisai | Phase 2 | 52 |
| Galunisertib + Placebo | Eli Lilly | Phase 2/3 | 65 |
| DSP-7888 | Sumitomo Pharma | Phase 1/2 | 41 |
| TP-0184 | Sumitomo Pharma | Phase 1/2 | 41 |
| Decitabine | Johnson & Johnson | Phase 2 | 52 |
| Epoetin alfa | Johnson & Johnson | Phase 2 | 52 |
| ZARNESTRA, tipifarnib, R115777 | Johnson & Johnson | Phase 2 | 52 |
| Decitabine | Johnson & Johnson | Phase 2 | 52 |